Go Pro
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$991.18
+0.7%		$938.16
$661.85
▼
$1,072.75
$62.07B0.47336,157 shs130,432 shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$34.47
+0.2%		$31.29
$23.62
▼
$35.43
$21.50B0.841.95 million shs1.94 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$158.55
+8.9%		$96.37
$22.28
▼
$176.66
$63.30B1.111.59 million shs14.02 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$783.72
+1.2%		$762.00
$541.00
▼
$859.34
$80.70B0.2822,173 shs225,667 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
+0.50%-1.76%-0.32%+12.19%+30.89%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
+0.73%+4.12%+4.75%+36.13%+21.81%
Moderna, Inc. stock logo
MRNA
Moderna
+1.29%+7.38%+125.91%+127.67%+486.23%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
+0.06%-4.09%-3.89%+27.00%+34.70%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$991.18
+0.7%		$938.16
$661.85
▼
$1,072.75
$62.07B0.47336,157 shs130,432 shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$34.47
+0.2%		$31.29
$23.62
▼
$35.43
$21.50B0.841.95 million shs1.94 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$158.55
+8.9%		$96.37
$22.28
▼
$176.66
$63.30B1.111.59 million shs14.02 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$783.72
+1.2%		$762.00
$541.00
▼
$859.34
$80.70B0.2822,173 shs225,667 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
+0.50%-1.76%-0.32%+12.19%+30.89%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
+0.73%+4.12%+4.75%+36.13%+21.81%
Moderna, Inc. stock logo
MRNA
Moderna
+1.29%+7.38%+125.91%+127.67%+486.23%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
+0.06%-4.09%-3.89%+27.00%+34.70%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenex SE stock logo
ARGX
argenex
2.88
Moderate Buy$1,158.6116.89% Upside
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2.85
Moderate Buy$39.5014.60% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$76.72-51.61% Downside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.58
Moderate Buy$802.182.36% Upside

Current Analyst Ratings Breakdown

Latest GMAB, REGN, ARGX, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/14/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$40.00
9/10/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$800.00 ➝ $920.00
9/9/2026
Moderna, Inc. stock logo
MRNA
Moderna
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$81.00
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Sell
9/3/2026
argenex SE stock logo
ARGX
argenex
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$1,150.00
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeNeutral ➝ Sell$40.00 ➝ $81.00
9/1/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
8/31/2026
argenex SE stock logo
ARGX
argenex
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$1,230.00 ➝ $1,250.00
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
CLSA logo
CLSA
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold
(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenex SE stock logo
ARGX
argenex
$4.25B14.60$21.58 per share45.93$118.34 per share8.38
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$3.72B5.78$1.62 per share21.22$9.10 per share3.79
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B32.56N/AN/A$22.14 per share7.16
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.34B5.63$42.50 per share18.44$295.66 per share2.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenex SE stock logo
ARGX
argenex
$1.29B$26.0438.1026.591.0132.19%43.59%36.66%N/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$963M$1.2727.1421.951.8619.08%14.89%7.73%11/5/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/5/2026 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.50B$40.4619.3715.511.5227.86%13.47%10.34%10/28/2026 (Estimated)

Latest GMAB, REGN, ARGX, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.37$0.54+$0.17$0.4910$1.12 billion$1.16 billion
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
7/30/2026Q2 2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$10.16$14.29+$4.13$12.23$3.82 billion$4.29 billion
7/21/2026Q2 2026
argenex SE stock logo
ARGX
argenex
$5.86$7.32+$1.46$7.32$1.45 billion$1.54 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.760.48%N/A9.29%N/A

Latest GMAB, REGN, ARGX, and MRNA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.940.46%8/18/20268/18/20268/31/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenex SE stock logo
ARGX
argenex
N/A
5.12
4.89
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.81
2.46
2.44
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.06
3.34
2.78

Institutional Ownership

CompanyInstitutional Ownership
argenex SE stock logo
ARGX
argenex
60.32%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%

Insider Ownership

CompanyInsider Ownership
argenex SE stock logo
ARGX
argenex
2.43%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
6.97%
CompanyEmployeesShares OutstandingFree FloatOptionable
argenex SE stock logo
ARGX
argenex
1,86362.56 million61.04 millionOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3,029623.78 million614.17 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,410102.96 million95.78 millionOptionable

Recent News About These Companies

Integrated Wealth Concepts LLC Reduces Position in Regeneron Pharmaceuticals, Inc. $REGN
September 17 at 3:51 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-integrated-wealth-concepts-llc-reduces-position-in-regeneron-pharmaceuticals-inc-regn-2026-09-17/
Regeneron’s ROXI-EVEREST Trial Puts a New Stroke Drug in the Spotlight
September 16 at 12:31 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/regenerons-roxi-everest-trial-puts-a-new-stroke-drug-in-the-spotlight?utm_source=marketbeat.com&utm_medium=referral
Bank of America Corp DE Purchases 101,469 Shares of Regeneron Pharmaceuticals, Inc. $REGN
September 16 at 3:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-purchases-101469-shares-of-regeneron-pharmaceuticals-inc-regn-2026-09-16/
Will Fianlimab-Libtayo Trial Misstatement Lawsuits Change Regeneron Pharmaceuticals' (REGN) Pipeline-Driven Narrative?
September 15 at 2:05 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/fianlimab-libtayo-trial-misstatement-lawsuits-141406881.html
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
September 15 at 8:49 AM  |  fool.comhttps://www.fool.com/coverage/better-buy/2026/09/15/novo-nordisk-vs-regeneron-pharmaceuticals-which-healthcare-stock-is-a-better-buy-in-2026/
Regeneron Pharmaceuticals (REGN) Could Be 5% Undervalued Following Trial Lawsuit News
September 15 at 4:04 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/regeneron-pharmaceuticals-regn-could-5-061056296.html
Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum
September 14 at 10:01 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-regeneron-highlights-dupixent-growth-cemdisiran-catalysts-and-eylea-hd-momentum-2026-09-14/
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 14 at 9:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4946169-regeneron-pharmaceuticals-inc-regn-presents-at-morgan-stanley-24th-annual-global-healthcare
Bispecifics Market to Gain Momentum During the Forecast Period (2026-2036) with Expanding Pipeline and Increasing Therapeutic Adoption | DelveInsight
September 14 at 1:01 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/bispecifics-market-gain-momentum-during-143100447.html
REGN DEADLINE ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. Investors to Today's September 14, 2026 Lead Plaintiff Deadline in Securities Class Action
September 14 at 12:46 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/regn-deadline-alert-hagens-berman-alerts-regeneron-pharmaceuticals-inc-investors-to-todays-september-14-2026-lead-plaintiff-deadline-in-securities-class-action-302877710.html
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
September 14 at 12:39 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20260914015061/en/class-action-deadline-tonight-faruqi-faruqi-llp-reminds-regeneron-regn-investors-of-securities-class-action-lawsuit-deadline-on-september-14-2026/
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
September 14 at 9:37 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20260914482755/en/regn-investors-have-opportunity-to-lead-regeneron-pharmaceuticals-inc.-securities-fraud-lawsuit-with-sbs-law/
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
September 14 at 9:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/14/3361205/0/en/regn-investors-have-opportunity-to-lead-regeneron-pharmaceuticals-inc-securities-fraud-lawsuit-with-sbs-law.html
WINTON GROUP Ltd Sells 12,978 Shares of Regeneron Pharmaceuticals, Inc. $REGN
September 14 at 4:23 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-winton-group-ltd-sells-12978-shares-of-regeneron-pharmaceuticals-inc-regn-2026-09-14/
NewEdge Advisors LLC Increases Stake in Regeneron Pharmaceuticals, Inc. $REGN
September 14 at 4:16 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-newedge-advisors-llc-increases-stake-in-regeneron-pharmaceuticals-inc-regn-2026-09-14/
Regeneron stock heads into the open after a 1.5 percent drop
September 13, 2026  |  ad-hoc-news.deA
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
September 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/13/3360655/9788/en/bronstein-gewirtz-grossman-llc-urges-regeneron-pharmaceuticals-inc-investors-to-act-class-action-filed-alleging-investor-harm.html
REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
September 13, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/regn-investor-deadline-tomorrow-regeneron-pharmaceuticals-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-robbins-geller-rudman--dowd-llp-announces-302870986.html
48-HOUR REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
September 12, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/48hour-regn-investor-deadline-regeneron-pharmaceuticals-inc.-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-1036541207
48-HOUR REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
September 12, 2026  |  newsfilecorp.comN
REGN 2-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit
September 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/12/3360600/32716/en/regn-2-day-deadline-alert-regeneron-pharmaceuticals-inc-investors-alerted-to-september-14-2026-lead-plaintiff-deadline-in-class-action-lawsuit.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
Illustration of a computer chip on a circuit board with an upward green stock chart line in a server room.
Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
By Thomas Hughes | August 31, 2026
Shoppers browse folded and hanging clothing in a retail apparel store with shelves and racks displayed.
3 Retail Stocks to Watch After a Big Consumer Earnings Week
By Dan Schmidt | August 29, 2026
Moderna logo displayed in a laboratory setting with a vaccine vial, petri dishes, and a microscope.
Moderna’s 177% Surge Has Investors Asking What Comes Next
By Sam Quirke | August 21, 2026
Scientist handles blood sample in lab, symbolizing early cancer detection.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
By Bridget Bennett | September 6, 2026
argenex stock logo

argenex NASDAQ:ARGX

$991.18 +6.49 (+0.66%)
As of 02:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$34.47 +0.07 (+0.19%)
As of 02:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Moderna stock logo

Moderna NASDAQ:MRNA

$158.55 +12.93 (+8.88%)
As of 02:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$783.72 +9.11 (+1.18%)
As of 02:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas